Sign in

Alzheimer disease: trials that stopped early

Trials on Alzheimer disease that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

86 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    Event-Related Potential (ERP) Components in Clinical Diagnosis

    Reason given in the registry

    “The sponsor stopped funding the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Dec 2025.

    Ended
    May 2025
    Run by
    Boston University
    Registry record
    NCT05673759
  2. Withdrawn

    Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease

    Reason given in the registry

    “sponsor decision to cancel project before enrollment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Dec 2025.

    Run by
    C2N Diagnostics
    Registry record
    NCT06856681
  3. Terminated

    A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

    Reason given in the registry

    “It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2025.

    Ended
    Aug 2024
    Phase
    Phase 2
    Run by
    Vivoryon Therapeutics N.V.
    Registry record
    NCT03919162
  4. Terminated

    A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

    Reason given in the registry

    “Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Dec 2025.

    Ended
    Jun 2024
    Phase
    Phase 2
    Run by
    reMYND
    Registry record
    NCT05478031
  5. Terminated

    Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease

    Reason given in the registry

    “Unexpected closure of study components -- the digital intervention (CBT-I) was no longer accessible, and alternatives were not feasible.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2025.

    Ended
    Jan 2024
    Run by
    University of California, San Francisco
    Registry record
    NCT03256539
  6. Suspended

    Development of Novel Measures for Alzheimer's Disease Prevention Trials

    Reason given in the registry

    “The NYSPI site is currently paused and has been paused since an institutional pause on human subjects research began in June 2023. The U.S. Department of HHS Office of Human Research Protections (OHRP) issued a pause on human subjects research.”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Oct 2025.

    Ended
    Aug 2026
    Run by
    New York State Psychiatric Institute
    Registry record
    NCT03900273
  7. Terminated

    Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

    Reason given in the registry

    “Terminated by Sponsor”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04795466
  8. Terminated

    Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

    Reason given in the registry

    “The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2025.

    Ended
    Sept 2024
    Phase
    Phase 3
    Run by
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Registry record
    NCT02446132
  9. Terminated

    Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Sept 2025.

    Ended
    Dec 2024
    Phase
    Phase 3
    Run by
    Cassava Sciences, Inc.
    Registry record
    NCT05026177
  10. Terminated

    Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Aug 2025.

    Ended
    Dec 2024
    Phase
    Phase 2
    Run by
    Cassava Sciences, Inc.
    Registry record
    NCT05352763
  11. Terminated

    Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease

    Reason given in the registry

    “A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2025.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Alzeca Biosciences, Inc.
    Registry record
    NCT05453539
  12. Withdrawn

    SNIFF - 3-Week Aptar CPS Device

    Reason given in the registry

    “protocol being rewritten and submitted as new study”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Jul 2025.

    Phase
    Phase 2
    Run by
    Wake Forest University Health Sciences
    Registry record
    NCT05006599
  13. Terminated

    Study of ASN51 in Adults With Early Alzheimer's Disease

    Reason given in the registry

    “Strategic decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jun 2025.

    Ended
    Nov 2024
    Phase
    Phase 2
    Run by
    Asceneuron S.A.
    Registry record
    NCT06677203
  14. Terminated

    Yizhi Baduanjin for Patients With Cognitive Impairment

    Reason given in the registry

    “Only 1 subject has been recruited.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Jun 2025.

    Ended
    Apr 2025
    Run by
    The University of Hong Kong
    Registry record
    NCT06453941
  15. Withdrawn

    A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

    Reason given in the registry

    “Company focus shifted”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2025.

    Run by
    ProgenaBiome
    Registry record
    NCT04100889
  16. Terminated

    Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study

    Reason given in the registry

    “Loss of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2025.

    Ended
    May 2025
    Run by
    University of Colorado, Denver
    Registry record
    NCT02612376
  17. Withdrawn

    Clinical Trial of AGB101 for Mild Cognitive Impairment

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.

    Phase
    Phase 2
    Run by
    AgeneBio
    Registry record
    NCT05986721
  18. Terminated

    Ultrasonic Neuromodulation for Treatment of Cognitive Impairment

    Reason given in the registry

    “IRB administrative closure”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.

    Ended
    Aug 2024
    Phase
    Phase 1/2
    Run by
    University of Utah
    Registry record
    NCT06135051
  19. Terminated

    Open-label Extension for Phase 3 Clinical Trials of Simufilam

    Reason given in the registry

    “sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.

    Ended
    Jan 2025
    Phase
    Phase 3
    Run by
    Cassava Sciences, Inc.
    Registry record
    NCT05575076
  20. Terminated

    TMS as a Treatment for Apathy in Alzheimer's Disease

    Reason given in the registry

    “Unable to fulfill recruitment goals”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.

    Ended
    Oct 2024
    Run by
    Massachusetts General Hospital
    Registry record
    NCT05389644
  21. Terminated

    Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

    Reason given in the registry

    “Lack of recruitment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 May 2025.

    Ended
    Feb 2025
    Phase
    Phase 2
    Run by
    Sunnybrook Health Sciences Centre
    Registry record
    NCT02085265
  22. Withdrawn

    Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

    Reason given in the registry

    “withdrawn by the PI”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Apr 2025.

    Ended
    Apr 2026
    Phase
    Phase 4
    Run by
    Wake Forest University Health Sciences
    Registry record
    NCT06169826
  23. Terminated

    A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

    Reason given in the registry

    “Sponsor's Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2025.

    Ended
    Aug 2024
    Phase
    Phase 3
    Run by
    Biogen
    Registry record
    NCT05310071
  24. Terminated

    ScentAware and OCT in MCI vs HC

    Reason given in the registry

    “slow enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2025.

    Ended
    Jun 2024
    Run by
    University of Wisconsin, Madison
    Registry record
    NCT06377241
  25. Withdrawn

    Effect of Neuronavigated Theta-Burst Transcranial Magnetic Stimulation (TBS) for Early Alzheimer's Disease

    Reason given in the registry

    “The study was terminated due to funding constraints and resource limitations that made further recruitment and continuation unfeasible.”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2025.

    Ended
    Mar 2025
    Run by
    Anhui Medical University
    Registry record
    NCT06524817
  26. Terminated

    Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

    Reason given in the registry

    “ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score.”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2025.

    Ended
    Oct 2024
    Phase
    Phase 2/3
    Run by
    LeonaBio
    Registry record
    NCT04886063
  27. Terminated

    An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living

    Reason given in the registry

    “The PI has moved to another institution”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Mar 2025.

    Ended
    Dec 2024
    Run by
    Bijan Najafi, PhD
    Registry record
    NCT05703490
  28. Terminated

    LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

    Reason given in the registry

    “Unable to recruit”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Mar 2025.

    Ended
    Apr 2024
    Phase
    Phase 3
    Run by
    LuMind IDSC Foundation
    Registry record
    NCT06860373
  29. Terminated

    A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

    Reason given in the registry

    “Sponsor's Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Feb 2025.

    Ended
    Jul 2024
    Phase
    Phase 3
    Run by
    Biogen
    Registry record
    NCT04241068
  30. Terminated

    Home Test for Measuring Plasma P-tau217 in Alzheimer's Disease

    Reason given in the registry

    “Lack of Funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Feb 2025.

    Ended
    Dec 2024
    Run by
    Insight Research Institute
    Registry record
    NCT06622135

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.